Clinical Trial Update: Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug [Phase 2]

View source ↗

Summary

Phase 2 study using [F-18]RGD-K5 PET to monitor response to an anti-angiogenic cancer therapy has completed, with enrollment spanning metastatic breast cancer, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• F-18 RGD-K5 (fluorine-18 labeled RGD-K5)

Snippet

Sponsor: Siemens Molecular Imaging | Conditions: Metastatic Breast Cancer, Metastatic Colon/Rectum Cancer | Phase 2 | Status: COMPLETED